Table 6.
Relationship between percentage change from baseline in biomarkers and time‐normalized C min (only everolimus patients)
| Biomarker | Patients, n | Samples used in the model, n | Percentage change per 2‐unit C min increase, Estimate (95% CI) | P value |
|---|---|---|---|---|
| VEGF‐A | 46 | 149 | 3.205 (−0.622, 7.180) | P = 0.101 |
| VEGF‐D | 57 | 228 | −6.429 (−9.275, −3.493) | P < 0.001 |
| sVEGFR1 | 46 | 156 | 2.203 (0.368, 4.072) | P = 0.019 |
| sVEGFR2 | 46 | 155 | −0.460 (−1.567, 0.659) | P = 0.416 |
| COL‐IV | 59 | 242 | −1.853 (−3.048, −0.644) | P = 0.003 |
| PLGF | 44 | 149 | 1.908 (−1.066, 4.972) | P = 0.208 |
| c‐Kit | 46 | 155 | 0.290 (−0.731, 1.321) | P = 0.576 |
COL‐IV, collagen type IV; PLGF, placental growth factor; VEGF‐A, vascular endothelial growth factor A; VEGF‐D, vascular endothelial growth factor D; sVEGFR1, soluble VEGF receptor 1; sVEGFR2, soluble VEGF receptor 2.